Halozyme Therapeutics
HALO
Hutchmed (China)
HCM
Teradata Corp
TDC
Dorian LPG
LPG
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
EXAS Exact Sciences
- 56.630
- -0.750-1.31%
Trading Dec 19 10:12 ET
10.48BMarket Cap-48.82P/E (TTM)
57.440High55.650Low267.10KVolume57.270Open57.380Pre Close15.09MTurnover0.15%Turnover RatioLossP/E (Static)185.08MShares79.62052wk High3.26P/B10.40BFloat Cap40.62452wk Low--Dividend TTM183.72MShs Float159.540Historical High--Div YieldTTM3.12%Amplitude0.220Historical Low56.513Avg Price1Lot Size
Exact Sciences Stock Forum
Sign in to post a comment
Futures tied to the S&P 500 and the Dow soared to record highs on Wednesday as Republican Donald Trump won the 2024 U.S. presidential election, capping his return four years after he was voted out of the White House.
Market Snapshot
Dow E-minis were up 1,308 points, or 3.09%, S&P 500 E-minis were up 133.5 points, or 2.30% and Nasdaq 100 E-minis were up 374 points, or 1.84%.
Pre-M...
Market Snapshot
Dow E-minis were up 1,308 points, or 3.09%, S&P 500 E-minis were up 133.5 points, or 2.30% and Nasdaq 100 E-minis were up 374 points, or 1.84%.
Pre-M...
15
1
$Exact Sciences (EXAS.US)$ break 56.9 fly again
1
$Exact Sciences (EXAS.US)$ guys relax sooner or later this will grow just not so soon
1
1
$Exact Sciences (EXAS.US)$ whats happening? why it keeps dropping?
$Exact Sciences (EXAS.US)$ Good opportunity to buy after correction, "not today" I shall buy in next week once volatility minimized. Good AI stoks but you can see good return not before 2025. I am bullish on it and it will remain my best pick for next 3-5 years invetment tenure.
2
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
No comment yet
Alen Kok : Oh